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Introduction: Certain strains of Cronobacter sakazakii can cause serious invasive
infections in children, mainly those <2months old and fed with powdered infant formula
(PIF). The infectious dose of C. sakazakii is unknown but evidence suggests that it is
approximately 1000 colony forming units (CFU). PIF is currently considered safe if its
end-product C. sakazakii level is <1CFU/g. In this study, we determined the lag time,
generation time (GT), and growth rate of five pooled C. sakazakii isolates to evaluate the
factors affecting contamination levels in reconstituted PIF.
Methods: 1.71 log CFU/ml of C. sakazakii were inoculated into 100 and 3000ml of
reconstituted PIF and incubated at 22 and 35°C. Growth was evaluated over a 24-h
period. ComBase was used for modeling.
Results: In 3000ml, the growth rate was 0.450.02 log CFU/h with a lag phase of
30.05 h and GT of 0.67 h at 22°C, while the growth rate was 0.730.01 log CFU/h
with a lag phase of 0.450.03 h and GT of 0.41 h at 35° C.
Conclusion: Cronobacter sakazakii grows rapidly in reconstituted PIF, especially
at 35° C.
Keywords: Cronobacter spp, hypothetical dose, powdered infant formula, contamination levels, infants
Introduction
Cronobacter spp. are only rarely isolated from clinical specimens (1). Some species and strains
have been isolated from normally sterile sites in hospitalized, elderly, and/or immunocompromised
adults. These isolates were obtained while the patients were being treated for clinically symptomatic
infections from more aggressive pathogens. Cronobacter were not causally linked to significant
symptomatic illness in these patients (2). Other Cronobacter species, especially some strains of
Cronobacter sakazakii, for example, strain type-4 (ST-4) or clonal complex 4 (CC4) (3), can infect
healthy young infants and cause invasive and devastating illness (4). The most frequent clinical
symptoms in reported cases of invasive pediatric Cronobacter infection are septicemia, necrotizing
Frontiers in Pediatrics | www.frontiersin.org August 2015 | Volume 3 | Article 721
Parra-Flores et al. Factors affecting Cronobacter contamination levels
enteritis, and/or meningitis; the latter is associated with CC4
strains (3–5). Diarrhea and urinary tract infections have also been
described (4–6). Reported mortality rates range from 42 to 80%
for neonatal meningitis and 15 to 25% for septicemia (7).
The vast majority of invasive Cronobacter infections have been
in infants <2months old who were fed powdered infant formula
(PIF). First reports of pediatric Cronobacter infections were in
hospital outbreak settings. When PIFs were included as potential
sources in outbreak investigations, contaminated PIF was repeat-
edly linked to the infections, microbiologically and epidemiolog-
ically (4). In 2002, health agencies recommended that PIF not be
fed to hospitalized premature infants because of these findings.
Since that time, most reported invasive Cronobacter cases have
occurred sporadically in full-term infants living at home (4).
Cronobacter contamination has been repeatedly found in,
and is sometimes endemic, in PIF and factories producing it.
Cronobacter have also been repeatedly found in the ingredients
used to make PIF and the factories processing these ingredi-
ents (8). PIF is not sterile and some of the organisms found in
PIF can be pathogenic, including Cronobacter (9). Preparation
utensils and equipment can become reservoirs of contamination
when PIF is contaminated (10). When contamination occurs
during production, it is not usually homogeneous throughout
the contaminated production lot. Rather, the pattern depends
on when and how microbial contamination occurred. For exam-
ple, contamination from a colonized piece of equipment could
be markedly sporadic. In general, Cronobacter contamination
of PIF has been highly heterogeneous and is characterized by
clustering and clumping, so that one portion of a contaminated
product could have no detectable contamination even though
another portion could contain concentrations above the infectious
dose (11).
For some pathogens, contamination alone is enough to seri-
ously jeopardize food safety. This is the case when the microor-
ganism has a very low-infectious dose, that is, only a few live
cells suffice to initiate the infectious process as in Salmonella and
Escherichia coli O157:H7 (12–14).
The Cronobacter infectious dose is unknown and likely varies
in relation to virulence factors and strain, as well as host species.
Most research related to Cronobacter infectious dose was done
before strain-typing schemes and assessment for virulence factors
were feasible. A growing body of evidence supports the presence
and role of various virulence factors in infantile Cronobacter
infection (15–17). Pagotto et al. (18) intraperitoneally injected
107 colony forming units (CFU) of one Cronobacter isolate into
rats and provoked the disease and death. More recent research
supports that the infectious dose for someCronobacter isolates can
be much lower. Iversen and Forsythe (19) proposed 1000CFU as
an approximate infectious dose. Research by Mittal et al. (17) and
Richardson et al. (20) support this value.
Because the pediatric infectious dose for some pathogenic
strains of Cronobacter is quite low, the initial contamination level
of the microorganism and its distribution in PIF are extremely
important factors in the risk associated with a contaminated
PIF product (21). Another relevant factor is PIF water rehydra-
tion temperature. The FAO/WHO (22, 23) and WHO guide-
lines recommend using water at 70°C for PIF rehydration (24).
Edelson-Mammel and Buchanan (25) estimated that using water
at temperatures over 70°C to rehydrate PIF contaminated with C.
sakazakii reduces 4 log CFU. Caubilla-Barron et al. (26) conclude
that initial inactivation with rehydration water at 70°C controls
any further growth that can occur in the cooled, reheated, and
consumed formula (27).
In 2010, two cases of hemorrhagic diarrhea in hospitalized
infants occurred in Mexico (6). Clinical isolates associated with
these cases matched isolates recovered from unopened cans of
PIF in the same hospital. The isolates were initially thought to
be Cronobacter. This led to further investigation, as well as deter-
mining if the PIF was rehydrated according to the WHO home
preparation guidelines, that is, 70°C. Water at this temperature
kills Cronobacter cells (28). However, water used in the hospital
was 45°C when mixed with PIF (6). Although healthcare workers
attempted to follow these guidelines, this investigation deter-
mined that when PIF was mixed, water temperature had likely
fallen to a level that would have incubated Cronobacter bacteria
rather than killed it. It was also determined that caretakers outside
the hospital setting frequently stored reconstituted PIF at room
temperature for prolonged periods of time, even in geographic
locations with high-ambient temperatures.
The objective of this study was to investigate the effect of tem-
perature and volume in the growth of C. sakazakii in R-PIF. A sec-
ondary objective was to create awareness about this public health
risk in developing countries where a lack of information is not
only limited to the general public but also to health professionals.
Materials and Methods
Bacterial Strains
Five strains of C. sakazakii were pooled as part of a microbi-
ological, environmental, and clinical survey conducted between
2009 and 2011; all strains had been isolated in a Mexican hospital.
To our knowledge, none of the five isolates were associated with
any clinical symptomatology. Four of the strains were isolated
from unopened cans of a single brand of PIF manufactured in
Mexico. The other strain came from the interior of a feeding bottle
that had been used to feed an infant. In the ongoing microbi-
ological assessment, all bacteria suspected of being Cronobacter
were initially evaluated using 16S rRNA amplification according
to Lehner et al. (29) and rpoB gene (30). Based on multilocus
sequence typing (MLST), the five strains described herein were
later confirmed to beC. sakazakii clonal complex ST297 (31). This
strain has not been associatedwith clinical disease in either infants
or adults.
Preparation of the Bacterial Suspension
The strains isolated from PIF were stored at 20°C in brain heart
infusion (BHI) (Oxoid, Basingstoke, UK) with 20% glycerol.
Strains were resuscitated in BHI at 35°C for 24 h in two successive
passes to attain itsmaximum logarithmic growth phase. Each indi-
vidual strain of C. sakazakii was separately evaluated in terms of
PIF growth prior to its inoculation as a pool. Cells were harvested
by centrifugation at 4500 rpm for 15min at room temperature.
Cell pellets were resuspended in peptone water 0.1% (Oxoid, Bas-
ingstoke, UK). Finally, the resulting suspension concentration was
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109 CFU/ml, which was confirmed by quantification in tryptic
soy broth (TSB, Oxoid, Basingstoke, UK). Decimal dilutions were
used for the inoculation of R-PIF and TSB.
To simplify the quantification of the pathogen in tryptic
soy agar (TSA, Difco, Becton Dickinson, Sparks, MD, USA),
C. sakazakii strains used in the test were resistant to 100 ppm
Rifampin (Rif+). The Rif+ mutants were obtained from pure cul-
tures by following the method published by Kaspar and Tamplin
(32). Bacterial strains were cultured individually on TSA with
Rifampin 100 ppm (Sanofi Aventi, Anagni, Italy) and incubated
at 37°C for 24 h according to the methodology described by Neal
et al. (33).
Reconstitution and Inoculation of R-PIF
Powdered infant formula was rehydrated (13% p/v) with 100 or
3000ml sterile distilled water at 45°C. Each reconstituted for-
mulas were inoculated with 1.71 log CFU/ml of the Cronobacter
strain cocktail. The initial concentration was 1.71 log CFU/ml
although the aim of the experiment was to reach 1.38 log
CFU/ml, which was the concentration found in the refrigerated
R-PIF reserve in the outbreak in Mexico (6). C. sakazakii ATCC
12868 and ATCC 29004 were grown in TSB and used as the
control strains; uninoculated R-PIF was used as the negative
control.
Assessment of Factors and Definitions
Cronobacter growth was studied using two temperatures (22 and
35°C) for two volumes (3000 and 100ml). These temperatures
were chosen based on the temperature of the milk kitchen and
water bath (temperature used to warm R-PIF before feeding the
infant). The volume was based on the quantity of PIF rehydration
and average PIF consumption.
Three independent replicas of the growth curves were per-
formed. Three samples from each replica were taken at 0, 1, 2, 3, 4,
6, 8, 12, and 24 h and plated on TSA supplemented with 100 ppm
Rifampin. Plates were then incubated at 35°C for 24 h.
Generation time (GT) is the time required by the cells to
duplicate. This parameter is estimated with the formula GT= log
(2)/µmax. The growth rate (µmax) was calculated using DMFit
version 2.0.
Maximum specific growth rate is the rate (log CFU per time
point) where the population is divided during the exponential
phase. The maximum is reached when the tangent of the curve
during the exponential phase changes and starts to decrease. This
is the kinetic parameter provided by DMFit when fitting the
growth curves.
Lag phase is the period duringwhich a cell or population adapts
to the environmental conditions before it begins to duplicate.
Statistical Estimation of Each Factor’s Effect
on Growth
Growth curves were fitted to the primary model of Baranyi and
Roberts (34) to estimate the lag phase (λ) and the maximum spe-
cific growth rate (µmax) with the DMFit version 2.0 (Combase™)
add-in for Excel 2007 Microsoft. An analysis of variance (SAS®
9.4) was used to determine the statistical significance of the effects
of temperature and volume on the growth rate.
Results
Cronobacter Growth Curves
For each of the studied factors, triplicates were averaged and a
good curve fit was obtained with DMFit Modeling (R2= 0.99)
(Figure 1).
The following parameters were determined from the fits. At
22°C in 3000ml, the growth rate was 0.45 0.02 log CFU/h with
a lag phase of 3 0.05 h and GT of 0.67 h. At 22°C in 100ml,
the growth rate was 0.32 0.02 log CFU/h with a lag phase of
3 0.02 h and GT of 0.94 h. At 35°C in 3000ml, the growth rate
was 0.73 0.01 log CFU/h with a lag phase of 0.45 0.03 h and
GT of 0.41 h. At 35°C in 100ml, the growth rate was 0.75 0.02
log CFU/h with a lag phase of 0.53 0.04 h and GT of 0.40 h.
The growth rates were compared by Tukey’s test (SAS®, 9.4).
The growth rate was affected by both temperature and volume
(p= 0.0018); the factor with the most significant influence was
temperature (p< 0.0001). When the interaction of these fac-
tors is evaluated, the growth rate is affected by volume at 22°C
(p< 0.044), but is not affected at 35°C (p= 0.818).
Estimated Time for Hypothetical Infectious Dose
The estimated time required to reach a hypothetical infectious
dose of 1000CFU (17, 19) calculated for 0.1, 1, 10, and 100CFU
of Cronobacter using ComBase™ is shown in Figure 2. The time
needed to reach 1000CFU at 35°C was 5.9 h when the initial
concentration was 0.1 CFU, 4.5 h for 1 CFU, 3.2 h for 10CFU,
and 1.8 h for 100CFU considering a lag phase of 0.45 h and GT
of 0.41 h. At 22°C, these values were 11.9, 9.7, 7.5, and 5.2 h,
respectively, with a lag phase of 3 h and GT of 0.67 h.
Discussion
In literature, a fairly narrow range of lag and GTs have been
reported for Cronobacter; however, the data on this topic are
sparse and isolates were not characterized in terms of virulence
factors or strain typing. For example, one study reported that
three clinical and three PIF isolates had lag times between 1.8 and
3.4 h with a mean of 2.75 h and GT between 37 and 44min when
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FIGURE 1 | Cronobacter mean growth curves in 100 and 3000ml at 35
and 22°C during 24h.
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FIGURE 2 | Time to reach a hypothetical 1000CFU dose in R-PIF at
35°C (A) and 22°C (B) with 0.1, 1, 10, and 100CFU using ComBase
generation time.
characterized further and no data were provided for incubation at
higher temperatures, for example, 35°C. In another study of nine
isolates (three clinical samples, three environmental samples, and
three PIF samples) in reconstituted PIF at 37°C, lag times were 2.2
to 3.0 h andGT for all isolates was 29min (35). Kandhai examined
one clinical and three PIF isolates and estimated a minimal lag
time of 1.7 0.44 h occurring between 37 and 39°C (36). Ghassem
et al. (37) evaluated three Cronobacter strains isolated from R-PIF
and one ATCC strain with ComBase and determined that GTs for
four Cronobacter strains were 3.64, 0.50, 0.29, and 0.27 h and the
lag phase in PIF was 10, 25, 37, and 45°C, respectively.
We examined the effects of two variables over time in relation
to the in vitro growth of the pooled C. sakazakii isolates grown
in reconstituted PIF: rehydration volume and incubation temper-
ature. We did not vary reconstitution temperature or inoculum
dose. At both evaluated temperatures, it is possible that rehy-
dration volume did not significantly affect growth because the
nutritional needs of our chosen inoculum were adequate at both
volumes, however, additional research will be needed to confirm
this hypothesis. This has practical implications for using PIF
in countries where some caretakers store reconstituted formula
at room temperature, especially in geographic areas with high-
ambient temperatures. This result is also important when formula
is stored appropriately and PIF is contaminated by virulent C.
sakazakii, which could continue to grow in an infant’s gastroin-
testinal tract. An infant’s body temperature would be in the range
of 36–40°C.
The WHO guidelines recommend that PIF be reconstituted
with water at 70°C to inactivate any Cronobacter contaminating
PIF (24, 28). However, there are at least three problems with
this recommendation. First, some health agencies are concerned
about the recommendation and do not support it (4). Second, it
is unlikely that this recommendation will be followed in a home
setting. Few caretakers will routinely measure the temperature
of boiled water before they mix it with PIF. Third, rehydration
instructions on some PIF labels do not comply with WHO guide-
lines. For example, in one Malaysian study, Abdullah Sani et al.
found that six brands mentioned temperatures from 40 to 55°C,
while all other brands indicated for previously boiled water to be
“cool” or “lukewarm” to prepare PIF (38).
It is estimated that the infectious dose for C. sakazakii is low,
approximately 1000CFU (17, 19, 20); however, this is not based
on the assessment of Cronobacter spp. virulent strains. Specif-
ically, there are no data evaluating C. sakazakii ST-4 or CC4
strains, which have recently been reported as the major cause of
Cronobacter meningitis in young infants (3, 16). Similarly, lag
time, GT, and growth rate have not been determined for specific
isolates associated with proven, invasive clinical infections. For
these strains, all these parameters may well be lower than those
reported in the literature, including in our own study.
In our study, we examined five apparently non-virulent strains
of C. sakazakii that were isolated from PIF-related hospital-based
sampling.We found that when we inoculated PIF at an initial level
1 CFU at 22°C, the generation or doubling timewas approximately
1.0 h at 22°C and 0.5 h at 35°C. This is within the range of values
found in previous studies, but not identical (26, 35–37). If we con-
sider that the pathogen has been quantified in PIF with contam-
ination levels of 0.22–1.61MPN/100g (39), 0.23–1.91MPN/100g
(40), and 0.023–2.3MPN/g (41), the possibility of illness associ-
ated with consumption at these contamination levels is very real.
The heterogeneous distribution of Cronobacter contamination in
PIF should be considered. A distribution of the inoculum size can
be observed in a batch of food and this markedly influences public
health risk. This heterogeneity can be due to the structural hetero-
geneity of the food matrix, incomplete mixing, incidental (post-
processing) contamination, and/or localized microbial growth
(42). It is critical to consider variability in microbial response
because the credibility of a microbial risk assessment is based
on its ability to consider the variability and uncertainty of each
parameter involved in estimating final risk (43). The presence
of a few atypical cells with short lag phase can unexpectedly
shorten population lag time (44), which may shorten food shelf-
life or, if pathogens are present in the food, increase the health
risk to consumers.
This study has a number of limitations. First, the strains we
tested were not associated with any known clinical illness. Second,
using 1CFU ignores the heterogeneous distribution of C. sakaza-
kii contamination in PIF. In practical terms, when end-product
testing results for a specific batch of product are below that level,
an absence of high-level contamination in isolated portions of
that batch is not guaranteed. Stratified random sampling enhances
the probability of detecting heterogeneous contamination in dry
PIF when compared to random sampling but will not necessarily
detect isolated clusters of contamination (42). A third possible
limitation of our study is that pooled strains do not accurately
represent the individual strains in the pool. We examined a pool
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of five strains of C. sakazaki all associated with PIF. Before we
pooled the isolates, we determined that the growth curves of the
strains were similar and reached mean maximum values of 1.0 to
1.5 109 (unpublished data). This was in part for convenience,
but also because multiple strains have been involved in PIF out-
breaks. Therefore, pooling isolates is more representative of the
“real-world” situation. By pooling the strains, we introduced a
naturally occurring uncertainty into our estimation.
In conclusion, 5.2 h at 22°C and 1.8 h at 35°C were needed
to reach a hypothetical infectious dose of 1000CFU (3 log) for
the pooled isolates when starting with 100CFU. The results of
the present study support that C. sakazakii grows rapidly in PIF,
especially at 35°C. There is an urgent need for ongoing training of
personnel working in milk kitchens regarding hygiene practices,
operational procedures, and the rigorous compliance of these
measures. Furthermore, parents of infants consuming PIF must
be informed about the risk of exposing their children when these
are not immediately fed prepared R-PIF. The WHO guidelines
regarding water rehydration temperature for R-PIF (>70°C) and
feeding time should be promoted through education of health
system users and professionals. Government should regulate PIF
product labels and health authorities should strictly control and
monitor PIF production. Whenever possible, infants <2months
of age should be only breast fed or fed ready-to-feed, pasteurized
formulas because these are commercially sterile.
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